Cinzia Colombo1*, Paola Mosconi1, Walter Villani1, Silvio Garattini2 hanno condotto un’indagine per verificare se la dichiarazione sul conflitto d’interesse sia chiara, completa e accessibile al pubblico.
Background: Many patients’ and consumers’ organizations accept drug industry funding to support their activities. As drug companies and patient groups move closer, disclosure become essential for transparency, and the internet could be a useful means of making sponsorship information accessible to the public. This survey aims to assess the transparency of a large group of Italian patient and consumer groups and a group of pharmaceutical companies, focusing on their websites.
Methodology/Principal Findings: Patient and consumer groups were selected from those stated to be sponsored by a group of pharmaceutical companies on their websites. The websites were examined using two forms with principal (name of drug companies providing funds, amount of funding) and secondary indicators of transparency (section where sponsors are disclosed, update of sponsorship). Principal indicators were applied independently by two reviewers to the patient and consumer groups’ websites. Discordances were solved by discussion. One hundred fifty-seven Italian patient and consumer groups and 17 drug companies were considered. Thirteen drug companies (76%) named at least one group funded, on their Italian websites. Of these, four (31%) indicated the activities sponsored and two (15%) the amount of funding. Of the 157 patient and consumer groups, 46 (29%) named at least one pharmaceutical company as providing funds. Three (6%) reported the amount of funding, 25 (54%) the activities funded, none the proportion of income derived from drug companies. Among the groups naming pharmaceutical company sponsors, 15 (33%) declared them in a dedicated section, five (11%) on the home page, the others in the financial report or other sections.
Conclusions/Significance: Disclosure of funds is scarce on Italian patient and consumer groups’ websites. The levels of transparency need to be improved. Disclosure of patient and consumer groups provided with funds is frequent on Italian pharmaceutical companies’ websites, but information are often not complete.
Citation: Colombo C, Mosconi P, Villani W, Garattini S (2012) Patient Organizations’ Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian Survey. PLoS ONE 7(5): e34974. doi:10.1371/journal.pone.0034974
Editor: Barbara Mintzes, University of British Columbia, Canada
Copyright: ß 2012 Colombo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: No external funding was received for this study.
Competing Interests: The study was supported by internal institutional funds from the Mario Negri Institute. In December 2011, the Mario Negri Institute, on behalf of the Laboratory of Medical Research on Consumer Involvement, received a 6000 euro grant from Pfizer to participate in discussions on a project supported by this drug company. This activity was not related in any way in content or timing to the work submitted here. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: firstname.lastname@example.org
1 Laboratory of Medical Research on Consumer Involvement, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy, 2 Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy